Tandem Diabetes Care, Inc. (TNDM) Stock Price & Analysis

Tandem Diabetes Care, Inc. (TNDM) closed at USD 19.68 on Wednesday, October 28, 2026, up 2.39% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 19.22; the Oct 28, 2026 session ranged USD 18.75–19.71 on volume of 2,137,718 shares. Market capitalization is $1.37B, with a 52-week range of USD 12.26–29.65 (NGM). Source: Nexqual, retrieved October 29, 2026 at 11:01 UTC.

Also available as compact Markdown for AI agents: nexqual.com/TNDM.md

Key facts (TNDM)

• Last four reported quarters (through Jun 30, 2026): revenue $1.04B, net income -$63.3M (-6.1% margin), free cash flow -$26.6M (SEC filings).
• Analysts: Buy (mean 2.40 on a 1–5 scale) (25 analysts), mean target USD 27.76 (range 18–50).
• Total return with dividends: 1Y +29.9% vs S&P 500 +13.6%; 5Y -85.6% vs S&P 500 +79.8%.
• Next earnings: 2026-11-05, EPS estimate USD -0.24, revenue estimate $266M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (TNDM)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (TNDM)

P/S 1.3x · EV/Sales 1.5x · P/B 10.5x · FCF yield -1.94% · Earnings yield -4.62% · Net debt $147M · EV $1.52B

Analysts (TNDM)

Consensus Buy (mean 2.40 on a 1–5 scale), 25 analysts; mean target USD 27.76 (low 18, high 50).

Rating changes, last 120 days:

Total return (dividends reinvested) (TNDM)

TNDM earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

TNDM recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

TNDM revenue by product line (quarter ended Jun 30, 2026)

TNDM revenue by region (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

TNDM company outlook (results filed Aug 6, 2026)

• “The Company has not reconciled adjusted EBITDA margin outlook to the most comparable GAAP outlook because it is not possible to do so without unreasonable efforts due to the 2 Exhibi”

Quoted word-for-word from the SEC 8-K results press release.

TNDM analyst estimates and revisions

TNDM options: expected move

Options price a move of about ±21.0% (±$4.08) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±18.4% on average.

30-day implied volatility 99.4% vs 51.7% realized over the last 30 trading days. Put/call ratio (volume) 0.1. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 11:01 UTC)

Technical Analysis (TNDM)

Nexqual's technical model rates TNDM "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 29, 2026 at 11:01 UTC.

Analyst Ratings (TNDM)

Wall Street analysts rate TNDM "Buy" based on 25 analysts, with a mean price target of USD 27.76 (range USD 18–50), per Nexqual as of October 29, 2026 at 11:01 UTC.

Earnings (TNDM)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 11:01 UTC.

Financials & Fundamentals (TNDM)

Source: Nexqual, October 29, 2026 at 11:01 UTC.

Financial Health Score (TNDM)

Nexqual rates Tandem Diabetes Care, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 11:01 UTC.

Ownership (TNDM)

Source: Nexqual, October 29, 2026 at 11:01 UTC.

Leadership (TNDM)

Tandem Diabetes Care, Inc. is led by John F. Sheridan, President, CEO & Director, per Nexqual as of October 29, 2026 at 11:01 UTC.

Major Backers & Investors (TNDM)

Notable institutional backers of Tandem Diabetes Care, Inc. include Sessa Capital IM, L.P., First Light Asset Management, LLC, GW&K Investment Management, LLC, according to Nexqual as of October 29, 2026 at 11:01 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 11:01 UTC.

From Tandem Diabetes Care, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)

Key Strengths & Strategy (as disclosed to the SEC)

• The FDA and the Food and Drug Branch of the California Department of Health Services enforce regulatory requirements by conducting periodic, unannounced inspections and market surveillance.
• Our technology solutions are now available in more than 25 countries.
• We rely on a combination of copyright, patent, trademark, trade secret and other intellectual property laws, non-disclosure agreements and other measures to protect our proprietary rights.
• The steps we have taken may not prevent the misappropriation of our intellectual property, particularly in foreign countries where the laws may not protect our proprietary rights as fully as in the United States.

Legal & Regulatory Risks (Item 1A, quoted)

• We do not maintain insurance to cover the expense or any liability that may arise from an intellectual property dispute.
• We may be subject to damages resulting from claims that we, or our employees, have wrongfully used or disclosed trade secrets or other proprietary information of our competitors.
• We may incur product liability losses, and insurance coverage may be inadequate or unavailable to cover these losses.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 11:01 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt